BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

被引：0
|
作者：
Yao, Sufei
Shang, Chengzhang
An, Gao
Guo, Chaoshe
An, W. Frk
Yang, Yi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2616
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A2616
引用
收藏
页数：2
相关论文
共 25 条
  • [1] Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer
    Yao, Sufei
    Shang, Chengzhang
    An, Gao
    Zhang, Ellen
    Lin, Qingcong
    Yang, Yi
    CANCER RESEARCH, 2023, 83 (08)
  • [2] Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors
    Fenn, K. M.
    Kalinsky, K.
    DRUGS OF TODAY, 2019, 55 (09) : 575 - 585
  • [3] Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer
    Huang, Wenpeng
    Li, Liming
    Zhou, Yuhan
    Yang, Qi
    Mixdorf, Jason C.
    Barnhart, Todd E.
    Hsu, Jessica C.
    Saladin, Rachel J.
    Liu, Chihao
    Rosenkrans, Zachary T.
    Engle, Jonathan W.
    Gao, Jianbo
    Kang, Lei
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [4] ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
    Ma, F.
    Qiu, F.
    Tong, Z.
    Wang, J.
    Shi, Y.
    Li, L.
    Yu, G.
    Shi, H.
    Wu, X.
    Liu, A.
    Zhang, Y.
    Wang, H.
    Cheng, Y.
    Yang, H.
    Li, H.
    Chang, J.
    Zhou, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S359 - S359
  • [5] A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics
    Zhong, Haihong
    Xiong, Yan
    Huang, Han
    Pan, Yuming
    Wang, Na
    Sun, Bin
    Liu, Shen
    Yuan, Wei
    Liu, Dingguo
    Fang, Jan
    Bao, Haifeng
    CANCER RESEARCH, 2024, 84 (06)
  • [6] VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond
    Wang, Wei
    Li, Jing
    Guan, Lingyu
    Xu, Man
    Yin, Qun
    CANCER RESEARCH, 2024, 84 (07)
  • [7] Development of Triple-negative breast cancer (TNBC) syngeneic models and TROP2-directed antibody-drug conjugate (ADC) surrogate to model therapeutic combinations
    Chou, Chih-Chien
    Kardos, Jordan
    Yang, Becky
    Orf, Jessica
    Dave, Rutwij
    Lai, Yurong
    Lee, Chingwei V.
    Papalia, Giuseppe A.
    Boyd, Kelli
    Diehl, Lauri
    Scholler, Nathalie
    CANCER RESEARCH, 2023, 83 (05)
  • [8] A novel EGFR x HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation
    Li, Zhuolin
    Shang, Chengzhang
    An, Gao
    Guo, Chaoshe
    An, W. Frank
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
  • [9] A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
    Zong, Hui-fang
    Li, Xi
    Han, Lei
    Wang, Lei
    Liu, Jun-jun
    Yue, Ya-li
    Chen, Jie
    Ke, Yong
    Jiang, Hua
    Xie, Yue-qing
    Zhang, Bao-hong
    Zhu, Jian-wei
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (08) : 1727 - 1739
  • [10] Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Zalath, Maria
    Mostafa, Ali
    Arrojo, Roberto
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2016, 76
123